2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. EGFR
  4. EGFR/HER2/DHFR-IN-1

EGFR/HER2-IN-7 是一种强效抗癌剂，对癌细胞具有高选择性，特异作用于乳腺癌细胞 MCF-7。EGFR/HER2-IN-7 是一种多重抑制剂，抑制 EGFR/HER2 激酶和 DHFR，IC50 分别为 0.153 μM，0.108 μM，0.291 μM。EGFR/HER2-IN-7 阻滞细胞周期在 G1/S 期，并诱导细胞凋亡 (apoptosis)。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

EGFR/HER2/DHFR-IN-1 Chemical Structure

EGFR/HER2/DHFR-IN-1 Chemical Structure

CAS No. : 2820126-37-0

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

EGFR/HER2/DHFR-IN-1 相关抗体

Top Publications Citing Use of Products

查看 EGFR 亚型特异性产品:

查看所有亚型
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

EGFR/HER2/DHFR-IN-1 is a potent anticancer agent with high selectivity against MCF-7 breast cancer cells. EGFR/HER2/DHFR-IN-1 is a multiple inhibitor of EGFR/HER2 kinase and DHFR, with IC50s of 0.153 μM, 0.108 μM, 0.291 μM, respectively. EGFR/HER2/DHFR-IN-1 arrests cell cycle at G1/S and induces cells apoptosis[1].

IC50 & Target

apoptosis; 0.153 μM (EGFR); 0.108 μM (HER2); 0.291 μM (DHFR)[1]
细胞效力
(Cellular Effect)
Cell Line Type Value Description References
HCT-116 IC50
6.08 μM
Compound: 39
Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells after 72 hrs by MTT assay
[PMID: 35964425]
HeLa IC50
4.78 μM
Compound: 39
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
[PMID: 35964425]
HepG2 IC50
3.48 μM
Compound: 39
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 35964425]
MCF7 IC50
1.83 μM
Compound: 39
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 35964425]
PC-3 IC50
12.74 μM
Compound: 39
Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
[PMID: 35964425]
WI-38 IC50
54.18 μM
Compound: 39
Antiproliferative activity against human WI-38 cells after 72 hrs by MTT assay
Antiproliferative activity against human WI-38 cells after 72 hrs by MTT assay
[PMID: 35964425]
体外研究
(In Vitro)

EGFR/HER2-IN-7 (compound 39) shows remarkable broad spectrum cytotoxic potency, with an IC50 value of 1.83 μM against MCF-7 breast cancer cell lines[1].
EGFR/HER2-IN-7 (1.83 μM) induces cell apoptosis by arreating cell cycle at G1/S[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

EGFR/HER2/DHFR-IN-1 相关抗体:

Cell Cycle Analysis[1]

Cell Line: HepG2 hepatocellular carcinoma, MCF-7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate and Hea cervical epithelioid carcinoma
Concentration: 0-1 mM
Incubation Time: 72 hours
Result: Inhibited EGFR/HER2 kinase and DHFR, while DHFR inhibition caused cell cycle arrest at the S phase while EGFR/HER2 kinase inhibition caused arrest at the G1 phase.

Apoptosis Analysis[1]

Cell Line: HepG2 hepatocellular carcinoma, MCF-7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate and Hea cervical epithelioid carcinoma
Concentration: 0-1 mM
Incubation Time: 72 hours
Result: Inhibited cancer cells growth and induced apopsosis with IC50s of 3.48 μM (HepG2), 1.83 μM (MCF-7), 6.08 μM (HCT-116), 12.74 μM (PC3), 4.78 μM (Hela), respectively.
体内研究
(In Vivo)

Caspase-3 is a lysosomal enzyme involved in apoptosis, and is used as a biomarker for detection of apoptotic cells[1].
EGFR/HER2-IN-7 (compound 39) (10 mg/kg; i.p.; once daily; 20 d) shows anti-breast cancer activity in vivo and increases caspase-3 immunoexpression in brease cancer mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Breast cancer with non-lactating mammary glands animal model in Swiss albino female mice (8-weeks-old)[1]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection; once daily; 20 days
Result: Inhibited tumor volume with reduction rate of 76.5%.
Reduced body weight with loss rate of 17.4%.
Showed the Caspase-3 score of 1.33.
分子量

379.23

Formula

C14H11BrN4O2S
CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

EGFR/HER2/DHFR-IN-1 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

EGFR/HER2/DHFR-IN-12820126-37-0EGFREpidermal growth factor receptorErbB-1HER1thiazole Imidazo[2,1-b]thiazolein vivo?anti-breast cancer assaypharmacophore predictionInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
EGFR/HER2/DHFR-IN-1
目录号：
HY-151154
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z